source
- FAIR Act could boost U.S. rare‑disease trial access and restore biotech leadershipIn a recent BioSpace podcast, host Jennifer C. Smith‑Parker talked with Max Bronstein of Aviva Strategies and Teresa Barnes of PF Warriors about a growing problem: U.S. patients are increasingly un…
- BMS trial sees patient death, analysts say drug mechanism still viableBristol Myers Squibb is running a phase 3 study of an LPA1 inhibitor, admilparant, for idiopathic and progressive pulmonary fibrosis. A patient death was reported after the trial was amended to inc…